Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencing data.
about
Emerging platforms using liquid biopsy to detect EGFR mutations in lung cancerLiquid biopsy genotyping in lung cancer: ready for clinical utility?Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.Circulating Cell-Free Tumour DNA in the Management of Cancer.The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer.Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase InhibitorsDynamics of circulating tumor DNA represented by the activating and resistant mutations in epidermal growth factor receptor tyrosine kinase inhibitor treatment.Circulating tumor DNA detection in lung cancer patients before and after surgeryTumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer.Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery.Early responses of EGFR circulating tumor DNA to EGFR tyrosine kinase inhibitors in lung cancer treatment.Liquid Biopsies in the Screening of Oncogenic Mutations in NSCLC and its Application in Targeted Therapy.Transient appearance of circulating tumor DNA associated with de novo treatment.The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC.Detection of Clonal and Subclonal Copy-Number Variants in Cell-Free DNA from Patients with Breast Cancer Using a Massively Multiplexed PCR Methodology.Monitoring gastric cancer progression with circulating tumour DNA.Numerical indices based on circulating tumor DNA for the evaluation of therapeutic response and disease progression in lung cancer patients.High-fidelity target sequencing of individual molecules identified using barcode sequences: de novo detection and absolute quantitation of mutations in plasma cell-free DNA from cancer patientsSelective identification of somatic mutations in pancreatic cancer cells through a combination of next-generation sequencing of plasma DNA using molecular barcodes and a bioinformatic variant filter.Quantitative analysis of the BRAF V600E mutation in circulating tumor-derived DNA in melanoma patients using competitive allele-specific TaqMan PCR.A Comparative Study for Detection of EGFR Mutations in Plasma Cell-Free DNA in Korean Clinical Diagnostic Laboratories.Neueste technologische Entwicklungen für die Analyse von zirkulierender Tumor-DNA
P2860
Q28082499-35C604DD-2183-4C48-998E-942B425A5A9AQ33567037-CBB130E4-C623-4A81-BBA1-9A7C8A144352Q34577740-E822D866-DB77-4AEB-AEC5-F1113B18F940Q35587176-1127B3F9-59D7-4A4A-93F4-7D2721469E9BQ35814162-6715B100-259A-43C7-B4BF-41B5D756CDD6Q36095650-66CE5A1A-64B8-40B2-8552-FCA48FC32B2FQ36558400-424BF950-9F2D-4A31-88FC-C1253A44A092Q36746250-8138D551-0004-46F4-BB08-83E0C058107FQ37264643-9B65EE95-232C-4F11-A36E-1CFC438AE390Q37462554-7C81BB58-7711-4400-A1F5-99405606A998Q37544357-7AFCC96C-DC83-4AAB-9C81-B802D07FDA95Q37593245-CB3FAC18-614D-4A28-9A86-EC2CA52C8BFBQ37687711-11ACAE03-6277-4262-8F2F-4F2B0CC0813DQ38859701-B5C15737-7DC3-41FE-BE11-52DBDCCAE67CQ39116247-5F92FDC3-2A37-4169-AE8D-D7F1884967C9Q41472736-8013CCA1-945E-4C19-89AF-6C5E36F3F82AQ41821680-6A06AFCA-5DE9-4154-9DCB-ED7386F56E18Q42275485-F829DB78-6C91-4A54-B8F8-3E3782EBCBECQ42431173-9D3F6009-438C-42E2-85FF-14E400CFC5FCQ42524460-BAAE2A3D-99F4-4475-AB44-561F55916C2AQ49924982-BD18E129-1D2E-49BB-8C59-5A2EC0857693Q53130491-0F3D6CA7-43C3-49B5-B6F0-FBE9CD027881Q55129047-A1FA0074-3966-4C02-B13E-43DA581AFD2CQ57636579-20487246-D11F-494A-AF9E-3F39B237DD05
P2860
Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencing data.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Quantitative identification of ...... on using deep sequencing data.
@ast
Quantitative identification of ...... on using deep sequencing data.
@en
type
label
Quantitative identification of ...... on using deep sequencing data.
@ast
Quantitative identification of ...... on using deep sequencing data.
@en
prefLabel
Quantitative identification of ...... on using deep sequencing data.
@ast
Quantitative identification of ...... on using deep sequencing data.
@en
P2093
P2860
P1433
P1476
Quantitative identification of ...... on using deep sequencing data.
@en
P2093
Fumio Imamura
Junji Uchida
Kazumi Nishino
Kazuya Taniguchi
Kikuya Kato
Shigeyuki Oba
Takako Okuyama
Toru Kumagai
Yoji Kukita
P2860
P304
P356
10.1371/JOURNAL.PONE.0081468
P407
P577
2013-11-21T00:00:00Z